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INTRODUCTION
Hepatitis C virus infection causes severe morbidity with
development of hepatic fibrosis leading to chronic liver
disease, cirrhosis and hepatocellular carcinoma.
Epidemiologically, Pakistan falls in the intermediate
prevalence zone for HCV infection, where infection rate
is between 4 – 6% and approximately 10 million
populations is affected.1 It is usually treated in Pakistan
with ribavarin-interferon therapy due to cost and the
prevalent genotype (type-3). Pegylated interferon is only
used when there is persistent positive RNA despite 24
weeks of therapy.2 With this approach, the reported
frequency of this subset of patients called the non-
responders, is about 16.8 – 17% in Pakistan.3,4 However,
these patients who are not responding to therapy are the
ones more likely to develop complications such as those
arising from fibrosis and steatosis.
Presence of steatosis has been frequently reported in
the HCV affected patients.5,6 It is even said to affect the
treatment outcome such as non-response, and the
natural history and progression of disease with onset
of complications.7 On the other hand, it may cause
confusion with ultrasound features of fibrosis.
Ultrasound is an important noninvasive means of
evaluating hepatic morphology particularly in the
presence of coagulopathy and ascites when biopsy is
contraindicated.8 To the best of authors' knowledge, no
published local (Pakistan-based) data exist on
ultrasound evaluation of hepatic fibrosis and steatosis;
there is a similar paucity of literature on the ultrasound
evaluation of liver in the HCV patients who did not
respond to ribavarin-interferon therapy while these are
the group of patients requiring regular morphologic
evaluation. The hitherto unexplored accuracy of
ultrasound in HCV non-responders constituted the
rationale of this study.
The precise objective of the study was to evaluate
the accuracy of ultrasound in diagnosis and grading of
steatosis and fibrosis in patients with HCV who had a
positive HCV RNA despite 24 weeks of ribavarin-
interferon therapy.
METHODOLOGY
It was a cross-sectional, analytical study carried out in
the Department of Radiology, Dow Medical College and
Civil Hospital, Karachi, between March 2008 and
August 2010. The study was approved by the Ethical
Review Board, Dow University of Health Sciences. Adult
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ABSTRACT
Objective: To determine the accuracy of ultrasound in the diagnosis and grading of steatosis and fibrosis in Hepatitis C
(HCV) patients not responding to ribavarin-interferon therapy.
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mild fibrosis, 89.74% for moderate fibrosis and 100% for gross fibrosis. The overall accuracy for detection of steatosis was
95.39% and that for fibrosis was 98.02%. Hepatic vein showed increased dampening of flow with advancing grades of
steatosis and fibrosis.
Conclusion: Ultrasound has a high accuracy in the diagnosis and grading of steatosis and fibrosis in HCV non-
responders. Mild fibrosis may confound the diagnosis of mild steatosis.
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Pakistani patients regardless of gender, with positive
HCV RNA after 24 weeks of therapy with ribavirin and
conventional interferon (non-responders) and being
considered for pegylated interferon therapy and liver
biopsy were included. The selected patients were further
divided into a steatosis positive (s+) group and a
steatosis negative (s-) group on the basis of ultrasound
findings. The former comprised HCV non-responders
showing steatosis of liver on u/s and the latter comprised
those who did not show hepatic steatosis on u/s. Using
WHO sample size calculator software, 80% study power,
and assuming a difference in accuracy (100% for biopsy
and 95% for ultrasound), the calculated sample size was
152 with equal number in both groups i.e. HCV in the
hepatic steatosis and HCV without hepatic steatosis.
Patients aged less than 15 years, those with history of
alcohol intake, other positive viral hepatitis markers such
as hepatitis-B, auto-immune hepatitis or drug induced
hepatitis, deposition disorder, concomitant HIV, and a
hepatic mass lesion (s) or ascites were excluded.
Selected patients underwent ultrasound of hepatobiliary
system or upper abdomen using convex probe followed
by ultrasound guided liver biopsy after written informed
consent. Presence or absence of fibrosis was docu-
mented on ultrasound in all patients prior to biopsy; and
graded into nil (absent), mild, moderate and gross as per
criteria laid down in Table I, modified from Nishiura et al.9
The ultrasound was conducted by the senior teaching
faculty member and principal researcher. The images
were reviewed by another radiologist of similar standing
and experience blinded to the grading given by the first
researcher. Grading of steatosis was in the steatotic
group only according to criteria led by Scatarige et al.10
Mild steatosis was defined as increased echogenicity of
hepatic parenchyma (equal as or greater than the body
of pancreas) with normal visualization of posterior
diaphragm and intra hepatic vessels' borders (IHVB's).
Moderate steatosis-increased echogenicity of hepatic
parenchyma with impaired visualization of posterior
diaphragm IHVB's. Severe/gross steatosis-increased
echogenecity of hepatic parenchyma with poor or no
visualization of posterior diaphragm, intra hepatic
vessels' borders and posterior portions of the right lobe
of liver. Nil meant absence of steatosis on ultrasound.
Final grades were assigned with consensus. Portal vein
congestion index (CI) and hepatic vein damping index
(DI) were also determined on Doppler ultrasound.
Ultrasound guided liver biopsy was then performed by
the principal researcher using standard technique
and precautions. A sample of at least 1 cm3 was
considered adequate. The specimen was then sent for
histopathology and findings were recorded with respect
to grade of steatosis - nil, mild, moderate and gross;
fibrosis stage, activity grade and Ishak score. Histo-
pathology based final diagnosis of liver status was made
as minimal hepatitis, mild hepatitis, chronic hepatitis and
chronic active hepatitis with impending cirrhosis.
Statistical analysis was carried out on Statistical
Package for Social Sciences (SPSS) version 19.
Relevant descriptive statistics were computed for
measures of central tendency and dispersion. Accuracy
of ultrasound for diagnosis and grading of steatosis and
fibrosis was calculated using histopathology as the gold
standard. The sensitivity, specificity and the negative
and positive predictive values were calculated for the
overall and the separate subgroups of the steatosis and
fibrosis. Mean values for continuous variables were
compared between the two main groups using t-test with
significance at p < 0.05.
RESULTS
There were a total of 152 subjects, 76 in each steatosis
and the non-steatosis groups. The overall female
subjects were 81 (53.3%) and males were 71 (46.7%) in
number. The overall mean age was 38.73 ± 9.24 years
ranging from 22 to 69 years. The mean overall BMI was
23.4 ± 3.02 kg/m2. The overall daily mean dietary fat
intake of the studied group was 15 ± 0.43 grams. The
NS group had 03 (3.9%) cases of type-1 and 73 (96.1%)
cases of HCV type-3; corresponding numbers were 04
(5.3%) and 72 (94.7%) in the steatotic group (p = 0.5).
Regarding the ultrasound findings, there was no
significant difference in the spleen size, portal vein size
and congestion index among the two groups, however,
the Damping index was significantly different among the
subgroups as described later. Overall, the liver was
mildly fibrotic (n = 50, 32.89%) and mildly steatotic in the
majority (n = 42, 55.26%) of the studied subjects.
Ultrasound accuracy in hepatic steatosis and fibrosis
Table I: Ultrasound scoring criteria used for staging fibrosis in this study modified from Nishiuri et al.9
Stage Criteria-parenchyma Criteria-inferior edge Criteria-liver surface
Mild fibrosis Heterogeneous coarsening scattered in central Sharp to blunt -the latter seen with high Smooth to rough
segments-may go undetected by low frequency frequency probe
probe (3.5 MHz) and visible by high frequency 
probe (5MHz) only
Moderate fibrosis Coarse, echogenic parenchyma in diffuse distribution Blunt to rounded-the latter seen with high Irregular
frequency probe, the former with low 
frequency probe 
Advanced or gross fibrosis Diffuse coarse echogenic irregular heterogeneous Rounded seen with low frequency probe Irregular to nodular
to nodular readily visible with low frequency probe
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Among the steatosis positive group on ultrasound, 38
had mild steatosis, 33 had moderate steatosis and 05
had gross steatosis. On histopathologic confirmation, 42
of these cases had mild steatosis, 29 had moderate
steatosis and 05 had gross steatosis (Table II). There
were 07 cases among the non-steatotic group who
turned out to have mild steatosis on histopathology
which gave an overall accuracy of 90.9% for the
exclusion of steatosis. All these cases had mild fibrosis
seen on both the histopathology and the ultrasound. The
accuracy for sonographic grading for gross steatosis
was 100%, 100% for moderate steatosis and 95.9% for
mild steatosis (Table III).
Overall, sonographically, there were 04 cases of no
fibrosis, 54 cases of mild fibrosis, 74 cases of moderate
fibrosis and 20 cases of gross fibrosis (Table IV). The
accuracy is given in Table V. Among the steatotic group,
11 (14.5%) had gross fibrosis, 27 (35.5%) had mild
fibrosis, 38 had moderate fibrosis and none had no
fibrosis. Conversely among the non-steatotic group, 09
had gross fibrosis, 27 had mild fibrosis, 36 had moderate
fibrosis and 04 had no fibrosis. Despite a relatively less
advanced stage of fibrosis in the non-steatotic group, the
difference was not statistically significant with p value of
0.234 on chi-square test.
The mean fibrosis (Ishak) score was 2.3 in the non-
steatotic group and 2.4 in the steatotic group (p = 0.4).
While the portal vein CI was not significantly different
among the sub-groups, there was significant difference
towards a higher DI in both steatosis and fibrosis as
their respective grades advanced. The mean DI in both
groups was 0.5.
DISCUSSION
This study evaluated a very important group of Chronic
Hepatitis C (CHC) patients i.e. non-responders to
ribavarin-conventional interferon therapy. The main
finding was a very high frequency of some degree of
fibrosis in these patients. In fact only 04 out of the 152
i.e. 2.63% were spared from fibrosis. Slow and
progressive fibrosis is a known feature of the CHC
infection particularly in the non-responders, and its
evaluation has an important bearing on the outcome.5,11
Steatosis, on the other hand, is a recognized predictor to
an unfavourable response to therapy and exert an
adverse effect on the natural progression of HCV
infection.3-8,11,12
The studied group of patients was a predominantly
non- obese cohort bordering on being overweight as
per Asian standards taking an overwhelmingly
carbohydrate-based diet. The liver was mildly fibrotic
and mildly steatotic in the majority of this group of non-
responders.
As there were only a very few cases of no fibrosis, this
caused a marked difference in the sensitivity and
specificity for the detection of mild fibrosis. Except for
this outlier, the values of sensitivity, specificity and
prediction of presence or absence of various grades of
fibrosis was fairly accurate ranging from 89 – 100%.
Iliopaulos et al. found a sensitivity of 71.1%, specificity of
72.9%, PPV of 58.7% and 82.3% NPV for ultrasound
based diagnosis of mild steatosis; corresponding values
for higher grades of steatosis, were 85.7%, 60.4%, 13%
and 98.4%.13 They found a much lower sensitivity
(13.6 –  27.4%) and specificity (62.5 – 66.3%) for the
ultrasound detection of fibrosis.13 Their NPV (exclusion
capability) for lower stages of fibrosis was low (19.5%)
and somewhat better for higher stage of fibrosis (75%).
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Table II: Distribution of steatosis and histopathological confirmation.
(Please note that those assigned a particular steatosis grade on
ultrasound but found to have another grade on histopathology acted
as false positive and false negative for ultrasound assigned grades as
applicable).
Histopathology steatosis grade Total
Gross Mild Moderate Nil
Us steatosis grade
Gross 5 (TP) 0 (TN) 0 (TN) 0 (TN) 5
Mild 0 (TN) 38 (TP) 0 (TN) 4 ( FP) 42
Moderate 0 (TN) 0 (TN) 29 (TP) 0 (TN) 29
Nil 0 (TN) 7 (FN) 0 (TN) 69 (TP) 76
Total 5 45 29 73 152
Table III: Accuracy analysis for the sonographic diagnosis of steatosis.
No steatosis Mild steatosis Moderate steatosis Gross steatosis
Sensitivity 90.9% 84.4% 100% 100%
Specificity 100% 100% 100% 100%
Positive 
predictive 
value 100% 100% 100% 100%
Negative 
predictive 
value 91.4% 93.69% 100% 100%
Table IV: Distribution of fibrosis and histopathological confirmation.
(Please note that those assigned a particular fibrosis grade on ultra-
sound but found to have another grade on histopathology acted as
false positive and false negative for ultrasound assigned grades as
applicable).
Histopathology fibrosis stage Total
Gross Mild Moderate Nil
Us fibrosis grade
Gross 16 (TP) 0 (TN) 4 (FP) 0 (TN) 20
Mild 0 (TN) 50 (TP) 4 (FP) 0 (TN) 54
Moderate 0 (TN) 4 (FN) 70 (TP) 0 (TN) 74
Nil 0 (TN) 3 (FN) 0 (TN) 1 (TP) 4
Total 16 57 78 1 152
Table V: Accuracy analysis for the diagnosis of fibrosis.
No fibrosis Mild fibrosis Moderate fibrosis Gross fibrosis
Sensitivity 25% 100% 89.74% 100%
Specificity 100% 96.07% 89.18% 97.05%
Positive 
predictive 
value 100% 92.59% 89.74% 80%
Negative 
predictive 
value 98.01% 100% 89.18% 100%
Conversely, the positive predictive value was 71.9% for
lower stages of fibrosis and only 9.4% for higher stages
of fibrosis.13 This wide variation can only be explained by
the higher BMI of their selected population (25 kg/m2).
Higher BMI values considerably affect the sonographic
diagnosis of steatosis.14 Moreover, Iliopaulos et al. found
no correlation between the sonographic grade and
histologic score.13 The present results are different,
likely to be due to lower BMI and more importantly
adherence to a standardized criteria for grading of
steatosis and fibrosis instead of using the 'bright liver
pattern' only. Another report from Iacobillis et al.
corroborated that u/s parameters had a specificity rate of
90% or greater in excluding bridging fibrosis.15 They
had used the Metavir system for histopathological
evaluation.15
While the portal vein CI was not significantly different
among the sub-groups, there was significant difference
towards a higher DI in both steatosis and fibrosis as their
respective grades advanced. The mean DI in both
groups was 0.5. A DI of 0.6 is said to be an important cut
off limit for monitoring the response to therapy.16
A systematic review by Smith and Sterling showed that
Doppler findings alone cannot differentiate between
grades of fibrosis and ultrasound sensitivity and
specificity do tend to vary between studies.17 However,
it improves upon combining various parameters be it
liver surface or portal vein size or splenic size or Doppler
indices or Doppler spectra in many possible
combinations.17 Same can be true for ultrasound
detection and grading of steatosis.18 The difficulty or
limitation of using Doppler as single criteria is likely to be
due to difficulty in reliable reproduction of Doppler
measurements.19 O'Donohue et al. evaluated multiple
Doppler parameters along with spleen size and found
that splenomegaly and hepatic vein waveform not only
reliably predicts significant fibrosis but these are
reproducible parameters as well.20 Hepatic vein
waveform provides good evaluation of cardiac and
hepatic physiology by tracing the direction, regularity
and phasicity of the spectral tracing.21 In this study,
majority of the patients had an abnormal waveform with
57.2% having biphasic and 12.5% having monophasic
waveforms. No significant difference was seen in the
proportion between groups and sub-groups. This can be
due to the presence of some degree of fibrosis in an
overwhelming majority of the patients. Non-triphasic
hepatic flow was found to be a helpful Doppler criterion
of differentiating between cirrhosis and CHC by
Haktamir et al.22
Many previous studies have reported a low accuracy
and low reliability of ultrasound regarding the evaluation
of steatosis and fibrosis in HCV infection; most were
retrospective in nature and strict grading criteria as
suggested by Nishiura et al.9 and Scatarige et al.10, were
not used. The authors used these criteria prospectively
in combination and utilized ultrasound probes of multiple
frequencies, changing the depth for focused study of
liver parenchyma and its gross morphology. This may be
responsible for the present improved results. There have
been reports of good reliability and accuracy of
ultrasound for diagnosing and grading both fibrosis and
steatosis when semi-quantitative measures, multiple
parameters and multi-frequency probes have been
used.9
Adopting a number of criteria as used in this study, may
avoid unnecessary biopsies,23 and help when liver
biopsy is contraindicated by ascites.
The limitations of this study were the highly skewed
absence of mild fibrosis and lack of obese controls. The
first was what was found and reported what we found in
this cohort. The second was based on ethical grounds. It
was a histopathology-confirmed study and biopsy for
histopathology in obese patients without liver disease
can not be taken only for the sake of obtaining controls.
CONCLUSION
Based on the present results, using objective criteria
including grayscale ultrasound and Doppler indices,
ultrasound can be utilized for differentiation, detection
and grading of fibrosis and steatosis in CHC non-
responders.
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